Comparative Pharmacology
Head-to-head clinical analysis: SODIUM FLUORIDE F 18 versus THALLOUS CHLORIDE TL 201.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM FLUORIDE F 18 versus THALLOUS CHLORIDE TL 201.
SODIUM FLUORIDE F-18 vs THALLOUS CHLORIDE TL 201
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positron-emitting radionuclide used for bone imaging; fluoride ion is incorporated into bone matrix via chemisorption onto hydroxyapatite crystals, reflecting blood flow and osteoblastic activity.
Thallous chloride Tl-201 is a potassium analog that is taken up by viable myocardial cells via the Na+/K+ ATPase pump. Its distribution reflects regional myocardial blood flow and cell viability. In areas of ischemia or infarction, uptake is reduced, creating a perusion defect.
2-10 mCi (74-370 MBq) intravenous bolus injection, single dose for positron emission tomography (PET) bone imaging.
111-148 MBq (3-4 mCi) intravenous injection for myocardial perfusion imaging; imaging begins 5-10 minutes post-injection.
None Documented
None Documented
The terminal elimination half-life is approximately 2-4 hours. Clinically, this allows for imaging within 1-3 hours post-injection.
Terminal elimination half-life: approximately 73 hours. Clinical context: The long half-life allows for delayed imaging (e.g., redistribution imaging for thallium-201 myocardial perfusion scans).
Renal (primarily). Approximately 70% of the administered dose is excreted unchanged in urine within 24 hours. Less than 10% is excreted in feces.
Renal: approximately 70% over 10 days; fecal: less than 30% over 10 days.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical